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Background: Gender affirming hormone therapy (GAHT), whilst considered the standard
of care in clinical guidelines for the treatment of many transgender (trans) people is
supported by low quality evidence. In this prospective longitudinal controlled study, we
aimed to examine the effect of newly commencing GAHT on gender dysphoria and quality
of life (QoL) over a 6 month period.
Methods: Adult trans (including those with binary and/or non-binary identities) people
newly commencing standard full-doses of masculinising (n = 42; 35 = trans masculine, 7 =
non-binary) or feminising (n = 35; 33 = trans feminine, 2 = non-binary) GAHT and
cisgender participants (n=53 male, n=50 female) were recruited to participate in this
longitudinal prospective study. This analysis of gender dysphoria measured by the Gender
Preoccupation and Stability Questionnaire and QoL measured by the RAND Short-Form
36 Health survey at baseline, 3 and 6 months after commencement of GAHT was a
prespecified secondary outcome. Dysphoria and QoL over time in those starting GAHT
compared to cisgender comparison group matched for their presumed sex at birth is
reported as the mean difference (95% confidence interval) adjusted for age.
Results: In trans people initiating masculinising GAHT, there was a decrease in gender
dysphoria with adjusted mean difference -6.80 (-8.68, -4.91), p < 0.001, and a clinically
significant improvement in emotional well-being [adjusted mean difference 7.48 (1.32,
13.64), p = 0.018] and social functioning [adjusted mean difference 12.50 (2.84, 22.15),
p = 0.011] aspects of QoL over the first 6 months of treatment relative to the cisgender
female comparison group. No significant differences were observed in other QoL
domains. In trans people initiating feminising GAHT, there was a decrease in gender
dysphoria [adjusted mean difference -4.22 (-6.21, -2.24), p < 0.001] but no differences in
any aspects of QoL were observed.n.org July 2021 | Volume 12 | Article 7177661
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Frontiers in Endocrinology | www.frontiersiConclusions: In the short-term, our findings support the benefit of initiating masculinising
or feminising GAHT for gender dysphoria. Masculinising GAHT improves emotional well-
being and social functioning within 6 months of treatment. Multidisciplinary input with
speech pathology and surgery to support trans people seeking feminisation is likely
needed. Further longitudinal studies controlled for other confounders (such as the
presence of social supports) contributing to QoL are needed.Keywords: transgender, gender dysphoria, quality of life, testosterone, oestradiolINTRODUCTION
Transgender individuals (trans) experience a gender identity
(which may be binary or non-binary) different from that which
they were presumed at birth, and often, but not always, this
gender incongruency is associated with significant psychological
distress, known as gender dysphoria (1, 2). Despite considerable
progress made by the trans community over the past decade in
regard to visibility and acceptance, trans people still face
significant obstacles and prejudice (3, 4), social stigma and
discrimination, leading to job and housing insecurity, verbal
and physical violence, and barriers to accessing appropriate
healthcare (3). Similarly, trans people experience alarmingly
high rates of mental health disorders compared to the general
population (5, 6). A recent study looking at self-reported mental
health diagnoses within the trans community has indicated that
73% of trans adults have been diagnosed with depression in their
lifetime, 67% have been diagnosed with anxiety, and 43%
attempted suicide in their lifetime (3). In contrast, self-
reported rates of depression, anxiety and suicide attempts for
the general population are indicated at 11.6%, 26.3%, and 3.2%
respectively (7). While transgender health research is still in its
infancy, research thus far has indicated that gender-affirming
interventions (gender counselling, gender confirmation surgery
and hormone therapy), as well as sociocultural factors (external
validation of one’s gender, support from family and friends) are
associated with improved well-being among transgender
individuals (8, 9). Access to such healthcare can be challenging
for some, and the largest contributing factor to this, as reported
by trans individuals, is an overall lack of medical professionals
who are experienced in the field (6, 9, 10). Other reported factors
include: financial and socioeconomic status, and discrimination
(10). Gender affirming hormone therapy (GAHT) is the current
standard treatment for people who experience gender dysphoria
(5). While there is a significant amount of expert-opinion based
evidence available regarding the benefits of GAHT for trans
people, the majority of existing research into gender dysphoria
and quality of life (QoL) focuses on mental health outcomes
following surgery, and there is scant clinical evidence available
regarding the effects of GAHT alone (5), particularly in regard to
gender dysphoria outcomes (11). Of the research that does exist,
a beneficial role of GAHT has been consistently suggested (6, 11–
22), however evidence quality is low, primarily consisting of
uncontrolled cross-sectional and retrospective cohort studies,
and only two studies specifically quantify changes in gender
dysphoria following GAHT (11, 23, 24). Consequently, existingn.org 2guidelines for the treatment of trans individuals contain broad
recommendations based on expert-opinion which has been
valuable in providing clinical care for the trans community but
is also the subject of critiques from some clinicians (2, 5). This
guideline ambiguity leads to varied interpretation of treatment
recommendations amongst clinicians, and a lack of consistent
training practices (5).
We aimed to assess the short-term effects (0-6 months) of
newly commencing GAHT on the QoL and gender dysphoria
experienced by trans individuals and compare these results with
age-matched cisgender individuals of the same presumed sex at
birth. Based on previous literature (11, 22–24), it was
hypothesised that GAHT would be associated with improved
QoL and reduced gender dysphoria for trans people relative to
cisgender comparison groups of the same presumed sex at birth.METHODS
Participants
A total of 77 trans (n = 35 initiating feminising GAHT, n = 42
initiating masculinising GAHT) and 103 cisgender (n = 53 male,
n = 50 female) participants were recruited from online and local
print advertisements, and primary or secondary care clinics
specialising in trans health in Melbourne, Australia. Cisgender
females and males in the community were individuals who
responded to local advertisements for a study on bone health.
Recruitment occurred between April 2017 – April 2020 for the
primary outcome of bone microarchitecture, and gender
dysphoria and QoL were prespecified secondary outcomes. The
research study is registered with the ANZ Clinical Trials Registry
ACTRN12617000584336. Trans individuals were included for
the study if they were aged 18 years or over, newly commencing
standard (full) doses of masculinising or feminising GAHT, and
were able to provide written informed consent to the study and
comply with study protocols. Cisgender individuals without
medical conditions or medications that contributed to
metabolic bone disease were included. Trans individuals were
excluded if they had any contraindications to GAHT use, had
previously used masculinising or feminising GAHT, or had a
history of gender-affirming surgery. Exclusion criteria for all
participants were the presence of metabolic bone disease or
receiving therapy that affects bone (glucocorticoids,
bisphosphonates, antiepileptic medication, use of HIV pre-
exposure prophylaxis). People presumed to be menopausal
(age > 50 years) (trans men and cisgender females) wereJuly 2021 | Volume 12 | Article 717766
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weeks of commencing GAHT. The research study is registered
with the ANZ Clinical Trials Registry ACTRN12617000584336.
Ethics
Ethics approval was received from the Austin Health Human
Research Ethics Committee (Austin/17/HREC/74) and all
participants provided written informed consent.
Design
The study incorporated a prospective controlled observational
study design. Trans participants newly initiating were divided
into the following groups: masculinising GAHT or feminising
GAHT. Comparison individuals were presumed sex at birth-
matched cisgender males and females who were not undergoing
hormone therapy and we had intended to match for age as
closely as possible. Final statistical analyses were adjusted for age.
A comparison group who were trans but not using GAHT were
not recruited as trans community members deemed that it would
not be ethical or acceptable to withhold GAHT for research
purposes. Participants completed the following outcomes at
baseline and 6 months.
Outcomes
Gender Dysphoria
Gender dysphoria was assessed using the Gender Preoccupation
and Stability Questionnaire (GPSQ). The GPSQ has been
validated in Australia for use as a tool to measure gender
dysphoria within the transgender community (25) and was
chosen for this study due to its ability to evaluate the
effectiveness of gender-affirming interventions in both binary
and non-binary transgender individuals. The questionnaire
includes 14 multiple choice questions designed to measure the
extent of an individuals’ preoccupation with gender, and the
stability of their own gender identity over the past 2 weeks (25).
Each question had 5 possible answers, corresponding to a score
of 1-5, with higher scores indicating higher levels of gender
dysphoria. Total scores were calculated by taking the summation
of all values. Total scores 28 were considered highly suggestive of
clinical gender dysphoria, and a change in score of 11 points or
more reliably indicated a change in the degree of gender
dysphoria (25).
Quality of Life
QoL was measured using the RAND Short Form-36 (SF-36)
Health Survey, a 36 item questionnaire which has been validated
for use to assess 8 domains of QoL: physical functioning (relating
to the extent of physical limitations), social functioning (relating
to one’s ability to participate in social activities), role limitations
due to physical health (relating to the extent individuals were
limited in work/activities due to physical health), role limitations
due to emotional health (relating to the extent individuals were
limited in work/activities due to mental health), pain (relating to
physical pain), energy/fatigue (relating to one’s energy levels/
vitality), general health (relating to one’s perceived physical
wellbeing), and emotional wellbeing (relating to perceivedFrontiers in Endocrinology | www.frontiersin.org 3mental wellbeing) (26). Each item was denoted a value of 0-
100, with higher scores indicating a better health state. Scores
were calculated by taking the averages from the values pertaining
to each QoL domain, thus producing eight different total scores
between 0-100 per visit (27). The SF-36 has been reliably used to
assess the QoL of individuals in various populations and
circumstances (26, 28, 29), including several that have assessed
the QoL of transgender individuals on GAHT (20, 21, 30).
Furthermore, it is a fast, inexpensive, and accurate tool
designed to be self-reported by individuals in order to monitor
and assess treatment outcomes (27, 28). The minimum clinically
important difference for the SF-36 is typically in the range of 3 to
5 points which translates into a 0.09-0.28 effect size range (31).
Statistical Analysis
Age was not normally distributed and is presented as median
(interquartile range). Descriptive statistics were otherwise
presented as mean standard deviation (SD for continuous
variables). Results were summarised as the mean difference [95%
confidence interval (CI)] between groups (transgender versus
comparison group) over time. Comparison between two groups at
baseline was conducted using a two-sample independent t-test
whenever a variable followed normal distribution, otherwise
nonparametric Mann-Whitney test was used. Categorical
variables at baseline were compared using Chi-squared test, or
Fisher’s exact test where cell counts are low. Linear mixed effects
model was used to test the differences between groups across time,
with a time by group interaction term and a random intercept for
individual participant, assuming an unstructured variance-
covariance structure. The interaction term coefficients were
reported, which indicates the change in trend across time between
groups (i.e., whether the groups follow the same pattern of change).
All models were adjusted for age. All participants recruited into the
study at baseline (n=180) were used in the linear mixed effects
model, in which missing data were handled via maximum
likelihood estimation. The significance level was defined as P <
0.05 (two-tailed).RESULTS
Baseline characteristics for the trans participants and cisgender
comparison group are summarised in Table 1 for each group.
The median age of the masculinising hormone therapy group
was 24.0 years (22.0-29.3) and feminising hormone therapy
group was 28.0 years (22.5-39.5) relative to cisgender females
[27.5 years (24.0-37.5)] and cisgender males [31.0 years (25.0-
41.0)] (Table 1).
Gender Dysphoria
Compared to the cisgender comparison groups, a significant
reduction in gender dysphoria within the first 6 months of
GAHT was observed for both the masculinising hormone
[adjusted mean difference -6.80 points (-8.68, -4.91), p < 0.001]
and feminising hormone [adjusted mean difference -4.22 points
(-6.21, -2.24), p < 0.001] groups, as shown in Table 2.July 2021 | Volume 12 | Article 717766
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As shown in Table 2, individuals initiating masculinising GAHT
showed a significant improvement in emotional well-being
(mental health) [adjusted mean difference of 7.48 (1.32, 13.64),
p = 0.018] as well as social functioning aspects of QoL [adjusted
mean difference 12.50 (2.84, 22.15), p = 0.011] relative to
cisgender female comparison group over the first 6 months of
treatment. Improvements in both aspects were greater than the
minimum clinically important difference (32). No significant
differences were observed in the remaining 6 domains: physical
functioning, role limitations due to physical functioning, role
limitations due to emotional problems, energy/fatigue, bodily
pain or general health score.
Individuals initiating feminising GAHT showed no
significant changes in QoL over the first 6 months relative to
the cisgender male group (Table 2).DISCUSSION
We demonstrate in this prospective controlled study that in trans
people initiating masculinising GAHT, that there is an
improvement in gender dysphoria and a clinically significant
improvement in emotional well-being and social functioning
aspects of QoL over the first 6 months of treatment relative to
cisgender female comparison group. In trans people initiating
feminising GAHT, there is an improvement in gender dysphoria,
but no differences in QoL as measured by the RAND SF-36
were observed.
Gender Dysphoria
The beneficial effects of GAHT on gender dysphoria have
previously been discussed in relation to changes in
psychological state, such as changes in body uneasiness (16,
17), social anxiety (6), and self-esteem (19), however specific
changes in gender dysphoria have rarely been quantified. To our
knowledge, this is the only longitudinal controlled analysis of
gender dysphoria, and our findings of improved dysphoria in
both the masculinising-hormone and feminising hormone
groups relative to the cisgender comparison group over 6Frontiers in Endocrinology | www.frontiersin.org 4months, are consistent with 2 previous longitudinal but
uncontrolled studies which reported lower levels of gender
dysphoria after starting GAHT as measured by the Utrecht
Gender Dysphoria Scale (23) or the Gender Identity/Gender
Dysphoria questionnaire (11). Notably, whilst our findings were
statistically significant, the degree of change (4.2 – 6.8 points) is
less than the minimum clinically significant difference of 11
points for GPSQ. This is likely related to the limited duration of 6
months follow up which may be insufficient to have a significant
effect on an individual’s physical characteristics and in turn, their
gender dysphoria. Moreover, contributors to gender dysphoria
are complex and GAHT alone may not impact on many other
confounders such as social gender role recognition, exposure to
discrimination and physical features unaffected by GAHT such
as genitalia.
Quality of Life
We have demonstrated improved emotional well-being and
social functioning aspects of QoL in trans people initiating
masculinising GAHT over 6 months compared with cisgender
females. Whilst no other controlled prospective studies have
been performed, our findings are consistent with an Italian
cohort study which followed trans men over the first 12
months of masculinising GAHT which showed improved QoL
related to body image (22). Moreover, several cross-sectional
studies in trans men which have all shown better QoL as
measured by SF-36 in those using GAHT compared to those
not on GAHT (20, 21, 33, 34). Such consistently positive changes
in multiple studies may be reflective of the effectiveness of
testosterone therapy in inducing masculinising physical
characteristics, and significantly reducing dysphoria, to a
greater magnitude than those init iating feminising
hormone therapy.
In contrast, we did not demonstrate a significant
improvement in QoL in trans women commencing feminising
GAHT relative to the cisgender comparison group. Multiple
cross-sectional studies examining QoL measured by SF-36 have
been performed comparing trans women on GAHT compared
with trans women not using GAHT. These have shown variable













General Characteristics Total Count 42 50 35 53
Age Median (IQR) 24.0 (22.0-29.3) 27.5 (24.0-37.5) 0.028 28.0 (22.5-39.5) 31.0 (25.0-
41.0)
0.651
Employment Status: N (%) Unemployed 4 (10.5%) 8 (17.0%) 0.010^ 8 (24.2%) 2 (4.1%) 0.018^
Self Employed 2 (5.3%) 1 (2.1%) 1 (3.0%) 1 (2.0%)
Casual/Part-time
Employment
21 (55.3%) 15 (31.9%) 13 (39.4%) 14 (28.6%)
Full Time Employment 8 (21.1%) 21 (44.7%) 9 (27.3%) 28 (57.1%)
Retired 0 (0.0%) 1 (2.1%) 2 (6.1%) 2 (4.1%)
Other 3 (7.9%) 1 (2.1%) 0 (0.0%) 2 (4.1%)
Lifetime Mental Health
Diagnoses: N (%)
Depression 25 (59.5%) 8 (16.0%) <0.001 16 (45.7%) 4 (7.5%) <0.001
Anxiety 24 (57.1%) 8 (16.0%) <0.001 14 (40.0%) 3 (5.7%) <0.001July 2021 | Volume 12 | Article^Global p-values have been reported for employment status and no post-hoc analyses were performed.717766
Foster Skewis et al. Hormone Therapy on Gender Dysphoriabetter (20, 34, 36) or no change (30, 37). Whilst the SF-36 is
widely used, it is unclear which measure is most appropriate in
trans women. Utilising the WHO QoL questionnaire, Manieri
et al. did find improved overall QoL in trans women over the first
12 months (22). Notably our relatively shorter follow-up over 6
months may be insufficient for feminising GAHT to have
maximal effect, and whilst dysphoria significantly improved,
many physical characteristics, such as voice pitch and bony
structure, which may contribute to social functioning or
gender role recognition are unchanged with GAHT alone andFrontiers in Endocrinology | www.frontiersin.org 5multidisciplinary support of gender transition (i.e., with speech
pathology, surgery) for trans people seeking feminisation may
be needed.
Limitations
There are multiple limitations to our study. The short follow-up
time of 6 months is likely insufficient to gain a complete and
thorough understanding of GAHT’s psychological effects,
however we were interested in short-term effects of GAHT.























Gender Preoccupation and Stability Questionnaire
0 months 41.4 (7.3) 42 19.9 (3.4) 50 42.1 (7.4) 35 18.4 (3.8) 53
3 months 36.7 (7.8) 38 19.6 (4.4) 49 38.1 (8.0) 34 18.6 (3.6) 52
6 months 33.8 (8.1) 36 19.1 (3.4) 46 -6.80
(-8.68, -4.91)




0 months 62.6 (18.1) 42 78.8 (13.6) 50 59.2 (19.1) 35 81.8 (10.8) 53
3 months 64.8 (15.2) 38 75.6 (16.2) 49 61.2 (20.0) 34 80.8 (12.2) 52
6 months 65.8 (15.3) 36 75.5 (15.1) 46 8.10 (-2.47,
18.67)
0.133 58.1 (20.9) 30 82.8 (11.0) 42 -7.01
(-17.57, 3.55)
0.192
Role limitations due to physical health
0 months 46.0 (38.9) 42 89.1 (24.4) 50 48.0 (39.5) 35 91.3 (22.1) 53
3 months 54.8 (38.1) 38 81.8 (31.7) 49 62.2 (41.7) 34 87.4 (26.9) 52
6 months 54.3 (36.0) 36 88.6 (29.3) 46 -0.67
(-13.03, 11.69)
0.915 50.6 (45.6) 30 94.9 (14.7) 42 -0.21
(-12.72, 12.30)
0.974
Role limitations due to emotional problems
0 months 44.9 (19.1) 42 61.2 (21.9) 50 45.9 (16.3) 35 65.7 (18.1) 53
3 months 48.7 (18.1) 38 62.4 (20.0) 49 46.8 (19.4) 34 65.1 (20.9) 52
6 months 48.1 (18.2) 36 58.8 (22.2) 46 9.21 (-7.53,
25.96)




0 months 61.7 (20.2) 42 80.3 (15.0) 50 66.3 (15.9) 35 77.6 (16.4) 53
3 months 67.1 (17.2) 38 81.4 (15.1) 49 67.3 (16.9) 34 72.6 (18.3) 52
6 months 66.5 (21.0) 36 78.9 (16.9) 46 6.27 (-0.81,
13.35)
0.082 65.4 (15.4) 30 72.1 (19.1) 42 1.93 (-5.24, 9.10) 0.597
Emotional Well-Being
0 months 77.6 (25.5) 42 87.0 (15.7) 50 88.0 (15.1) 35 87.3 (15.0) 53
3 months 78.7 (23.9) 38 86.4 (15.6) 49 87.8 (12.7) 34 88.4 (15.0) 52
6 months 80.8 (23.0) 36 86.1 (15.0) 46 7.48 (1.32,
13.64)
0.018 83.6 (11.9) 30 86.3 (15.1) 42 -2.54 (-8.76, 3.67) 0.421
Social Functioning
0 months 84.4 (23.9) 42 97.0 (8.1) 50 89.9 (20.9) 35 89.3 (25.0) 53
3 months 84.2 (23.4) 38 93.6 (17.6) 49 92.2 (11.3) 34 96.1 (11.4) 52
6 months 88.7 (18.7) 36 93.2 (20.7) 46 12.50
(2.84, 22.15)




0 months 81.0 (35.7) 42 95.7 (15.2) 50 95.0 (13.3) 35 95.0 (15.2) 53
3 months 85.8 (32.6) 38 92.6 (21.3) 49 89.2 (23.4) 34 90.6 (24.6) 52
6 months 81.5 (35.8) 36 96.6 (13.4) 46 4.83 (-2.37,
12.02)




0 months 64.6 (22.9) 42 91.6 (13.2) 50 72.5 (23.0) 35 93.5 (11.9) 53
3 months 72.1 (23.8) 38 87.8 (19.5) 49 71.7 (19.9) 34 90.6 (17.1) 52
6 months 72.2 (26.0) 36 87.2 (20.1) 46 4.09 (-1.43,
9.62)
0.146 66.2 (29.0) 30 95.1 (9.3) 42 2.40 (-3.14, 7.94) 0.395July 2021 | Volume 12 | ArticleMean differences are adjusted for the age of the participant and all participants at baseline were used in the linear mixed effects model, in which missing data were handled via maximum
likelihood estimation. Gender dysphoria was measured by the Gender Preoccupation and Stability Questionnaire, with lower scores indicating less gender dysphoria. The remaining
domains are part of the RAND SF36 Health Survey whereby higher scores indicate better QoL.
Bold indicates statistically significant finding.717766
Foster Skewis et al. Hormone Therapy on Gender Dysphoriaidentified as trans. A controlled trial in trans people randomised
to GAHT or no GAHT would allow the best understanding of
GAHT’s effect on gender dysphoria and QoL, however the
conduction of such a trial is considered by many trans
community members to be unethical, given the existing
difficulties in accessing healthcare experienced by many who
desire GAHT. As such, a cisgender comparison group were used.
We used the locally developed GPSQ to measure gender
dysphoria, although this has not been validated as a tool to
measure changes in dysphoria over time.
However, this is the only prospective controlled study
examining gender dysphoria and QoL in trans individuals
newly commencing GAHT, thus validation from future studies
and longer term follow up is required.CONCLUSIONS
In the short-term, our findings support the benefit of initiating
feminising or masculinising GAHT on gender dysphoria.
Masculinising GAHT improves emotional well-being and
social functioning within 6 months of treatment however there
are many other confounders which can contribute to gender
dysphoria or QoL other than the changes in physical
characteristics induced by GAHT. These confounders include
the presence of dysphoria towards one’s voice, chest or genitalia
which may not be relieved with GAHT, the presence of a
supportive home, school or work environment, relationship
status or sexual function. Multidisciplinary input to holistically
support trans people, particularly those seeking feminisation will
likely be of benefit. Further longitudinal studies controlled for
confounders contributing to QoL will provide greater insights on
the benefit of GAHT specifically on gender dysphoria.Frontiers in Endocrinology | www.frontiersin.org 6DATA AVAILABILITY STATEMENT
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